Visby Medical, founded in 2010 and headquartered in San Jose, California, has raised a total of $386 million across multiple funding rounds, including a $100M Series E in March 2022, a $35M follow-up Series E in June 2022, and a $55M Series F in June 2025, achieving a $1 billion valuation. With 251 employees, the company develops portable, instrument-free PCR diagnostics for infectious diseases, serving hospitals and clinics globally. Backed by investors such as Pitango, Cedars Sinai, and Catalio Capital, Visby Medical is expanding production and R&D.